--- title: "Actuate Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286501055.md" datetime: "2026-05-15T03:14:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286501055.md) - [en](https://longbridge.com/en/news/286501055.md) - [zh-HK](https://longbridge.com/zh-HK/news/286501055.md) --- # Actuate Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.24. EBIT: As of FY2026 Q1, the actual value is USD -5.786 M. Actuate Therapeutics, Inc. operates as a single segment in the U.S. and has an accumulated deficit of - $160,233,450 as of March 31, 2026, having incurred significant operating losses and negative cash flows from inception. #### Operational Metrics - **Net Loss:** The net loss for the three months ended March 31, 2026, was - $5,625,749, an improvement from - $6,317,024 for the same period in 2025. - **Loss from Operations:** The loss from operations was - $5,705,956 for the three months ended March 31, 2026, compared to - $6,365,584 for the same period in 2025, representing a decrease of $659,628. - **Total Operating Expenses:** Total operating expenses decreased to $5,705,956 for the three months ended March 31, 2026, from $6,365,584 for the same period in 2025. - **Research and Development (R&D) Expenses:** R&D expenses decreased by $655,075 to $2,565,244 for the three months ended March 31, 2026, from $3,220,319 in the prior year period. This decrease was primarily due to a $1,253,182 reduction in external clinical study expenses to $581,189, and a $200,087 decrease in Chemistry, Manufacturing & Control (CMC) related costs to $236,767. These decreases were partially offset by an increase of $445,676 in nonclinical and biomarker studies to $538,077 and an increase of $352,518 in personnel and consulting expenses to $1,209,211. - **General and Administrative (G&A) Expenses:** G&A expenses remained relatively stable at $3,140,712 for the three months ended March 31, 2026, compared to $3,145,265 for the same period in 2025. Professional and consulting fees decreased by $167,917 to $970,768, and other expenses decreased by $3,962 to $375,287, while personnel-related expenses increased by $167,326 to $1,794,657, mainly due to a $203,544 increase in non-cash stock-based compensation expense. - **Other Income (Expense), Net:** This increased to $80,207 for the three months ended March 31, 2026, from $48,560 for the same period in 2025, driven by higher interest income of $85,269 in Q1 2026 compared to $53,623 in Q1 2025 due to a higher average cash balance. #### Cash Flow - **Cash and Cash Equivalents:** As of March 31, 2026, cash and cash equivalents were $8,134,004, down from $13,159,423 as of December 31, 2025. - **Net Cash Used in Operating Activities:** Net cash used in operating activities was - $5,017,327 for the three months ended March 31, 2026, compared to - $4,618,740 for the same period in 2025. - **Net Cash Used in Financing Activities:** Net cash used in financing activities was - $8,092 for the three months ended March 31, 2026, compared to - $133,477 for the same period in 2025. This included - $527,716 for taxes from withholding common stock on RSU settlement, partially offset by $519,624 net proceeds from the At-the-Market (ATM) Facility. #### Unique Metrics and Funding - **ATM Facility:** During Q1 2026, Actuate Therapeutics, Inc. sold 198,793 shares of common stock for net proceeds of $519,624 under its ATM Facility, with approximately $99.5 million remaining capacity as of March 31, 2026. An additional 213,550 shares were sold for net proceeds of $585,739 through May 13, 2026. - **Committed Equity Facility:** No shares were issued under this facility during Q1 2026, with 3,364,407 shares of common stock remaining in capacity as of March 31, 2026. #### Future Outlook and Strategy Actuate Therapeutics, Inc. is focused on developing cancer therapies through GSK-3 inhibition, with its lead product, elraglusib, showing promising results in its Phase 2 mPDAC study which met its primary endpoint. The company has received FDA clearance for a Phase 1⁄2 clinical study for an oral tablet formulation of elraglusib and plans for future Phase 2 or registrational studies, contingent on additional funding. Management anticipates that current cash and cash equivalents will not meet operational and capital needs beyond July 2026, necessitating additional capital and indicating substantial doubt regarding its ability to continue as a going concern without further funding. ### Related Stocks - [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md) ## Related News & Research - [Baxter Q2 2026 Earnings Preview](https://longbridge.com/en/news/294224876.md) - [What to Expect From Ulta Beauty’s Q2 2026 Earnings Report](https://longbridge.com/en/news/293941254.md) - [Vale updates financial events calendar for 2026](https://longbridge.com/en/news/294418484.md) - [Equatorial Energia updates financial calendar for 2026 disclosures](https://longbridge.com/en/news/294368263.md) - [Ciena's Q3 2026 Earnings: What to Expect](https://longbridge.com/en/news/293952665.md)